Inquiry Basket
Loading ......
Methotrexate (MTX) is a folate antagonist widely used in clinical practice for the treatment of cancer, autoimmune disorders, and inflammatory diseases. High-dose methotrexate is commonly administered in oncology, while low-dose regimens are standard in conditions such as rheumatoid arthritis and psoriasis. Despite its effectiveness, methotrexate has a narrow therapeutic window, and excessive drug exposure may result in severe adverse effects, including renal impairment, hepatotoxicity, bone marrow suppression, and gastrointestinal toxicity.
Figure 1. Simplified mechanism of MTX action.(Sources:Kocur A, et al.; 2024)
Accurate measurement of methotrexate levels in biological samples is therefore essential for therapeutic drug monitoring, toxicity prevention, and treatment optimization. Reliable detection methods allow clinicians to assess drug clearance, adjust dosing regimens, and guide rescue therapy, making methotrexate testing a critical component of patient management.
Methotrexate is most commonly measured in serum or plasma, particularly in patients receiving high-dose therapy. In certain research or pharmacokinetic studies, methotrexate may also be detected in urine or cerebrospinal fluid. The choice of sample type depends on clinical context, timing after drug administration, and the purpose of the analysis.
Regardless of the matrix, analytical methods must provide sufficient sensitivity and specificity to accurately quantify methotrexate across clinically relevant concentration ranges. This requirement has driven the widespread adoption of immunoassay-based detection systems in routine laboratories.
Several analytical techniques are available for methotrexate measurement. Chromatographic methods such as HPLC and LC-MS/MS are known for their high analytical specificity and are often used as reference or confirmatory methods. However, these approaches typically require complex sample preparation, expensive instrumentation, and specialized technical expertise.
In contrast, immunoassays offer a more practical solution for routine testing. Their rapid turnaround time, compatibility with automated analyzers, and ease of operation make them especially suitable for clinical environments where timely results are essential.
Immunoassays detect methotrexate through specific antibody–antigen interactions. Because methotrexate is a small molecular compound, most assays employ a competitive binding format. In this system, methotrexate in the patient sample competes with a labeled methotrexate analog for binding to a limited amount of anti-methotrexate antibody.
The detected signal is inversely proportional to the concentration of methotrexate in the sample. By comparing the signal to a calibration curve generated using known standards, accurate quantification can be achieved. This principle underlies multiple immunoassay platforms currently used in clinical diagnostics.
Enzyme Immunoassay (ELISA)
ELISA-based methotrexate assays are widely used in both clinical and research laboratories. They offer good sensitivity, reproducibility, and flexibility, and can be adapted to manual or automated workflows. ELISA is particularly useful for laboratories performing batch testing or assay development.
Fluorescence Polarization Immunoassay (FPIA)
FPIA is a homogeneous immunoassay method that does not require separation steps. It has been extensively used for therapeutic drug monitoring and is well suited for high-throughput clinical analyzers.
Chemiluminescent Immunoassay (CLIA)
CLIA-based assays provide high sensitivity and a broad dynamic range. These assays are commonly integrated into fully automated diagnostic platforms and are favored for their speed, consistency, and analytical performance.
Particle-Enhanced Turbidimetric Inhibition Immunoassay (PETINIA)
PETINIA measures changes in turbidity resulting from immune complex formation. It is compatible with standard clinical chemistry analyzers and offers rapid, cost-effective methotrexate measurement.
Immunoassays are widely adopted for methotrexate detection because they combine analytical reliability with operational efficiency. Minimal sample preparation reduces hands-on time and improves reproducibility, while automation enables high-throughput testing in busy clinical laboratories.
Importantly, immunoassays provide concentration ranges that align well with clinical decision thresholds. This makes them particularly valuable in monitoring high-dose methotrexate therapy, where rapid results are critical for timely intervention.
Detecting methotrexate accurately is essential for balancing therapeutic efficacy and patient safety. While advanced analytical techniques remain valuable in specialized settings, immunoassay-based methods continue to serve as the backbone of routine methotrexate monitoring. Their combination of specificity, speed, and scalability makes immunoassays a reliable and widely trusted approach for methotrexate detection in both clinical and research environments.
Methotrexate has a narrow therapeutic window, meaning that the difference between an effective dose and a toxic dose can be small. Monitoring methotrexate levels helps clinicians adjust dosing, evaluate drug clearance, and prevent serious adverse effects, especially during high-dose therapy.
Methotrexate is most commonly measured in serum or plasma. In certain research or pharmacokinetic studies, urine or cerebrospinal fluid may also be used, depending on the clinical or experimental purpose.
Common detection methods include immunoassays, high-performance liquid chromatography (HPLC), and liquid chromatography–tandem mass spectrometry (LC-MS/MS). Immunoassays are most widely used in routine clinical laboratories due to their speed, automation, and ease of use.
Immunoassays offer rapid turnaround time, minimal sample preparation, and compatibility with automated analyzers. These advantages make them well suited for therapeutic drug monitoring in hospital and diagnostic laboratory settings.
Most methotrexate immunoassays use a competitive binding format. Methotrexate in the sample competes with a labeled methotrexate analog for binding to specific antibodies. The resulting signal is inversely related to the methotrexate concentration in the sample.
Reference
| Target | Cat. No. | Product Name | Host | Application | |
| MTX | DPATB-H81809 | Anti-Methotrexate polyclonal antibody | Goat | ELISA, RIA | Inquiry |
| DMAB-WZ0004 | Anti-Methotrexate monoclonal antibody | Mouse | IA | Inquiry | |
| DPABY-912 | Anti-Methotrexate polyclonal antibody | Sheep | ELISA, Pr* | Inquiry | |
| DPABY-070 | Anti-Methotrexate (C-terminal) polyclonal antibody | Sheep | ELISA | Inquiry | |
| DMABB-JX341 | Mouse Anti-Methotrexate monoclonal antibody, clone MTX | Mouse | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| MTX | DAGB319 | Methotrexate [HRP] | HRP | IA | Inquiry |
| DAGA-351B | Methotrexate [BSA] | BSA | LFIA | Inquiry | |
| DAGA-351K | Methotrexate [KLH] | KLH | Immunogen | Inquiry | |
| DWT109 | Methotrexate Standard solution | N/A | Inquiry | ||
| DAG-WZ3635O | Methotrexate [OVA] | OVA | IA | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| MTX | DEIA-US209 | Methotrexate ELISA kit | 96T | Human, mouse, rat | Quantitative | Serum, plasma and urine | Inquiry |
| DEIA-XYZ209 | Methotrexate ELISA kit | 96T | Human | Quantitative | Serum, Plasma | Inquiry |
Loading ......
